Nelson L. Levy
Chief Executive Officer at CoreTechs Corp.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David C. Demirjian | M | - |
zuChem, Inc.
 zuChem, Inc. Wholesale DistributorsDistribution Services zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL. | 23 years |
| Thomas M. Loarie | M | - |
Bryologyx, Inc.
 Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | 8 years |
| John H. Abeles | M | 78 |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | - |
| Paul A. Wender | M | - |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | - |
| Rajni Aneja | F | - |
zuChem, Inc.
zuChem, Inc. Wholesale DistributorsDistribution Services zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL. | - |
| Sam Kongsamut | M | - |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | 7 years |
| Clinton H. Severson | M | 75 |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | - |
| Tom L. Churchwell | M | - |
zuChem, Inc.
zuChem, Inc. Wholesale DistributorsDistribution Services zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL. | - |
| Douglas S. Stewart | M | - |
zuChem, Inc.
zuChem, Inc. Wholesale DistributorsDistribution Services zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL. | - |
| Francis Michael Racine | M | - |
zuChem, Inc.
zuChem, Inc. Wholesale DistributorsDistribution Services zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL. | - |
| J. Grant Brewen | M | - |
zuChem, Inc.
zuChem, Inc. Wholesale DistributorsDistribution Services zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL. | - |
| James McConoughey | M | - |
zuChem, Inc.
zuChem, Inc. Wholesale DistributorsDistribution Services zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL. | - |
| Jenett Bruce | M | - |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | - |
| Yanhui Ma | M | - |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | - |
| David Ager | M | - |
zuChem, Inc.
zuChem, Inc. Wholesale DistributorsDistribution Services zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Todd Simpson | M | 63 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 9 years |
| James Johnson | M | 67 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 7 years |
| Miles White | M | 69 | 37 years | |
| H. Parker | F | 68 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 16 years |
| Paul Clark | M | 76 | 14 years | |
| G. Kirk Raab | M | 88 | 4 years | |
| Patrick W. McNallen | M | - | 5 years | |
| Michael Perry | M | 64 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 14 years |
| William D. Smithburg | M | 85 | - | |
| Michael J. Collins | M | 67 | - | |
| Brian Thomas Hett | M | - | 2 years | |
| Mark D. Aaron | M | - |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 years |
| Robert Bencher | M | - | - | |
| Munir Ahmad Shaikh | M | 81 | 4 years | |
| Bruce H. Phelps | M | - | 12 years | |
| Michael Fiechtner | M | - | 12 years | |
| Stephen W. Fesik | M | 70 | - | |
| Richard J. Marasco | M | 67 | - | |
| B. G. Susan Robinson | F | 62 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 11 years |
| Thomas A. Hurwich | M | 63 | 29 years | |
| Joseph Redmond | M | 64 | 6 years | |
| Lisa Giles | F | 65 | 10 years | |
| William Grossman | M | 54 |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | - |
| David Pearce | M | - | 16 years | |
| Richard Lesniewski | M | - | 26 years | |
| Shawn M. Marcell | M | 62 | 7 years | |
| Christopher A. Bleck | M | 66 | 18 years | |
| Douglas Bryant | M | 66 | 24 years | |
| Timothy Ring | M | 66 | 10 years | |
| Roger L. Hawley | M | 71 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 5 years |
| Perry Karsen | M | 69 | 11 years | |
| Michael J. Piechoski | M | 69 | 3 years | |
| David Schubert | M | 57 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 years |
| Vaughn Himes | M | 63 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 years |
| Irene C. Kerr | F | 74 | 10 years | |
| William E. Brown | M | 69 | 25 years | |
| Barrie J. Carter | M | 79 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 16 years |
| Jay Luly | M | 67 | 14 years | |
| Louis P. Lacasse | M | 67 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 8 years |
| Mark P. Richmond | M | 92 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 9 years |
| Jack Lief | M | 78 | 11 years | |
| William Dempsey | M | 73 | 25 years | |
| Joseph M. Davie | M | 84 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
| William C. Houghton | M | 81 | 11 years | |
| Jack L. Bowman | M | 91 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 11 years |
| Hing Leung Sham | M | 71 | 23 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 61 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nelson L. Levy
- Personal Network
